Project Grant R01CA292658
Award Date
7/5/24
Completion Date
6/30/29
Dollars Obligated
$597K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
This National Cancer Institute (CFDA 93.396 - Cancer Biology Research) Project Grant award of $447,944 to Baylor College of Medicine supports research to characterize the role of the transcription factor NRF2 in driving metastasis and therapy resistance in high-risk pediatric hepatoblastoma (HB) patients. The overarching goal is to thoroughly elucidate the molecular mechanisms underlying HB tumor cell dissemination, which can inform the development of targeted therapies to minimize metastasis,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Health Research, Inc. provides $719,799.00 to conduct research to determine the impact of metabolic adaptations on the tumor microenvironment and immune response in metastatic triple-negative breast cancer (TNBC). The research aims to investigate the mechanisms by which the bifunctional enzyme PFKFB4 regulates metabolic and genetic plasticity in the hypoxic tumor microenvironment, and...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports research to dissect the immunomodulatory effects of natural killer (NK) cells on anti-tumor immune responses. The $530,015 award to the Fred Hutchinson Cancer Center in Seattle, WA aims to define how tumor-intrinsic features regulate NK cell phenotype and function, elucidate the mechanisms controlling NK cell production of the cytokine FLT3LG, and investigate the regulation of NK cell...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Health Research, Inc. provides $700,690 to support research on the molecular mechanisms underlying breast cancer bone metastasis. The key objectives are to: Determine the molecular mechanisms driving the activation of the YAP/TAZ transcriptional coactivators in breast cancer bone metastasis. Investigate the functional role of YAP/TAZ-driven metabolic reprogramming in the microscopic...
This federal Project Grant award, provided by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports research to elucidate the molecular mechanisms driving metastatic recurrence and impaired natural killer (NK) cell function in HER2-positive breast cancer. The University of Texas Southwestern Medical Center, the prime awardee, will utilize innovative preclinical models and unbiased approaches to investigate how disseminated HER2-positive breast cancer...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) in the amount of $121,460 supports research to investigate the role of the NRF2-methylosome interaction in lung cancer. The research aims to biochemically characterize the functional binding partners of NRF2, a key transcription factor implicated in lung cancer, with a focus on its interaction with the PRMT5 methylosome complex. The research will map the NRF2-PRMT5 interaction, characterize...
This $180,632 federal Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research to discover and validate compounds that can block cancer cell engulfment of mesenchymal stem cells, which has been linked to increased metastatic potential in breast cancer. The two-year project, running from May 2025 to April 2027, will leverage high-throughput microfluidic technology to conduct a comprehensive screening of 2,726 compounds with...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Northwestern University in the amount of $895,779. The funding will support research to advance the understanding and treatment of HER2-positive breast cancer brain metastases. Key aspects of the project include: Genetic analysis of patient tissue samples to identify risk factors for brain metastases in HER2-positive breast cancer. Real-time visualization of cancer cells and...
The National Cancer Institute awarded a $639,790 Project Grant (CFDA 93.396 Cancer Biology Research) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The grant, which runs from July 3, 2024 to June 30, 2029, supports research to investigate the role of chromatin remodeling, specifically the histone H3.3 variant deposited by the HIRA complex, in regulating the dormancy and proliferation of metastatic breast cancer cells. The research aims to unveil HIRA...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $548,915 to the Fred Hutchinson Cancer Center in Seattle, WA to conduct research on a novel tumor suppression axis in small cell lung cancer (SCLC). The research aims to leverage cellular models, genetically engineered mouse models, and human tumor datasets to elucidate the biological roles of a stress-activated protein kinase (SAPK) pathway in...